Department of Radiation Oncology, Changhai Hospital Affiliated to Navy Medical University, Shanghai, China.
Department of Hepatic Surgery, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Clin Respir J. 2024 May;18(5):e13749. doi: 10.1111/crj.13749.
The neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) were significant and succinct indicators of systemic inflammation. We assessed the influence of stereotactic body radiotherapy (SBRT) on NLR and PLR in patients with locally advanced non-small cell lung cancer (LA-NSCLC).
We reviewed the medical data of patients with LA-NSCLC who underwent SBRT between 1 January 2013 and 31 December 2018. NLR and PLR values recorded at pre- and post-SBRT were examined. We assessed the correlation between pre/post-SBRT NLR and PLR and survival outcomes. The decision tree evaluation was conducted using Chi-square automatic detection.
In total, 213 patients were included in the study with a median follow-up duration of 40.00 (ranging from 5.28 to 100.70) months. Upon dichotomization by a median, we identified that post-SBRT NLR > 5.5 and post-SBRT PLR > 382.0 were negatively associated with shorter overall survival (OS). In the multivariate assessment, post-SBRT PLR > 382.0 was the only factor. Based on post-SBRT PLR, tumor locations, and tumor stage, we categorized patients into low, medium, or high-risk groups.
Post-SBRT PLR > 382.0 correlated with survival in patients undergoing SBRT. The decision tree model might play a role in future risk stratification to guide the clinical practice of individualized SBRT for LA-NSCLC.
中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）是全身性炎症的重要且简洁的指标。我们评估了立体定向体部放疗（SBRT）对局部晚期非小细胞肺癌（LA-NSCLC）患者 NLR 和 PLR 的影响。
我们回顾了 2013 年 1 月至 2018 年 12 月期间接受 SBRT 的 LA-NSCLC 患者的医疗数据。检查了 SBRT 前后记录的 NLR 和 PLR 值。评估了 SBRT 前后 NLR 和 PLR 与生存结果的相关性。使用卡方自动检测进行决策树评估。
共纳入 213 例患者，中位随访时间为 40.00 个月（范围为 5.28 至 100.70）。中位数二分法后，我们发现 SBRT 后 NLR>5.5 和 SBRT 后 PLR>382.0 与总生存期（OS）较短相关。在多变量评估中，SBRT 后 PLR>382.0 是唯一的因素。基于 SBRT 后 PLR、肿瘤位置和肿瘤分期，我们将患者分为低危、中危或高危组。
SBRT 后 PLR>382.0 与接受 SBRT 治疗的患者的生存相关。决策树模型可能在未来的风险分层中发挥作用，以指导 LA-NSCLC 的个体化 SBRT 临床实践。
